V
Vironexis
AAV gene-therapy platform delivering single-dose, off-the-shelf T-cell engagers for cancer treatment
About Vironexis
Vironexis is a clinical-stage biotechnology company founded in 2021 in San Diego, California that develops AAV-delivered T-cell immunotherapies for cancer. Its TransJoin in-vivo protein engineering platform uses a non-integrating AAV vector to make the patient's own liver continuously secrete a bispecific T-cell engager from a single intravenous dose, avoiding the ex-vivo manufacturing, lymphodepletion and repeat dosing associated with CAR-T and bispecific antibody therapies. The company was co-founded by CEO Samit Varma, scientist Brian Kaspar and physician-scientist Timothy Cripe, whose research at Nationwide Children's Hospital underlies the platform, which is licensed from the hospital.
Vironexis has built a pipeline of more than ten product candidates across hematologic malignancies, solid tumors and autoimmune disorders. Its lead programs are VNX-101, a CD19+ therapy for acute lymphoblastic leukemia and lymphoma, and VNX-202 for HER2+ cancers, both of which are in Phase 1/2 clinical trials. Lead candidate VNX-101 has received FDA Fast Track, Rare Pediatric Disease and Orphan Drug designations. The company operates a lean research-and-development model, funding its programs through venture capital and partnerships.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2021
- Headquarters
- San Diego, United States
- Employees
- 16
- Open positions
- None listed
- Dealroom signal
- 83.0/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Immunotherapy, Spinout, Biotech and Pharma, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SEED✓Equity / VC | Sep 2024 | $26M | $104M | Capital Factory · Drive Capital · Moonshots Capital · Future Ventures | ↗ |
| SPINOUT✓Other financing | Jan 2021 | $0 | — | Nationwide Children's Hospital | — |
Growth signals
Latest recorded traffic for Vironexis is 2.8K monthly website visits, up 1900% over the last three months. Vironexis's team grew 33.3% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed4 investors entered at this stage
Drive Capital
Future Ventures
Capital Factory
Moonshots Capital
Other known investors2 additional known investors
Nationwide Children's Hospital
Rev1 Ventures
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Vironexis on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Vironexis’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.